Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31451989 | 0.86 | ALDH1A1 (0.45) | ALDH1A1MAPTHTTLMNAPDGFRB | |
| SCHEMBL31305114 | 0.84 | ALDH1A1 (0.44) | ALDH1A1MAPTHTTLMNAPDGFRB | |
| SCHEMBL5628047 | 0.84 | KMT2A (0.56) | ALDH1A1MAPTHTTLMNAPDGFRB | |
| SCHEMBL525661 | 0.84 | PDGFRB (0.47) | ALDH1A1MAPTHTTPDGFRBFGFR1 | |
| SCHEMBL25249572 | 0.83 | ALDH1A1 (0.43) | ALDH1A1MAPTHTTLMNAPDGFRB | |
| SCHEMBL29858663 | 0.83 | ALDH1A1 (0.43) | ALDH1A1MAPTHTTLMNAPDGFRB | |
| SCHEMBL11430270 | 0.83 | ALDH1A1 (0.54) | ALDH1A1MAPTHTTLMNAMEN1 | |
| SCHEMBL4581669 | 0.83 | MAPT (0.49) | ALDH1A1MAPTHTTLMNAPDGFRB | |
| SCHEMBL31305220 | 0.82 | ALDH1A1 (0.47) | ALDH1A1MAPTHTTLMNAMEN1 | |
| SCHEMBL7241356 | 0.82 | ALDH1A1 (0.47) | ALDH1A1MAPTHTTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024220626-A1 | SMALL MOLECULE MODULATORS OF OGG1 | AZKARRA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| CN-116621839-A | EZH2 degradation agent and preparation method and application thereof | 四川大学 | 2023-08-22 | — | — | CN | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| CN-112920176-B | Bifunctional compound capable of inducing PRC2 protein complex core subunit degradation, pharmaceutical composition and application | 四川大学华西医院 | 2022-11-04 | — | — | CN | disclosed |
| WO-2021262684-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2016074566-A1 | GLUCOSIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF | 镇江新元素医药科技有限公司 | 2016-05-19 | — | — | WO | disclosed |
| CN-104817554-A | Glucoside derivatives and pharmaceutical compositions thereof | ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD | 2015-08-05 | — | — | CN | disclosed |
| WO-2012061602-A1 | ISOINDOLINONE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20110275630-A1 | ISOINDOLINONE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2011-11-10 | — | — | US | disclosed |
| US-20100076051-A1 | ISOINDOLINONE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | US | disclosed |
| US-20060287370-A1 | Isoindolinone kinase inhibitors | CURTIN MICHAEL L | 2006-12-21 | — | — | US | disclosed |
| US-7129260-B2 | Isoindolinone kinase inhibitors | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1633710-A1 | ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS | Abbott Laboratories (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050026976-A1 | Isoindolinone kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| WO-2004108672-A1 | ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | ALDH1A1 2214/4885MAPT 4203/4885HTT 2757/4885 |
| US-20060287370-A1 | Isoindolinone kinase inhibitors | ABL1, LCK, MAP3K7 | ALDH1A1 2410/4885MAPT 1734/4885HTT 3671/4885 |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | ALDH1A1 2214/4885MAPT 4203/4885HTT 2757/4885 |
| US-20050026976-A1 | Isoindolinone kinase inhibitors | ABL1, LCK, MAP3K7 | ALDH1A1 2410/4885MAPT 1734/4885HTT 3671/4885 |
| US-20100076051-A1 | ISOINDOLINONE KINASE INHIBITORS | ABL1, LCK, MAP3K7 | ALDH1A1 2410/4885MAPT 1734/4885HTT 3671/4885 |
| US-20110275630-A1 | ISOINDOLINONE KINASE INHIBITORS | MAP3K7, MAP3K5, MAP3K20 | ALDH1A1 2721/4885MAPT 1836/4885HTT 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.